Clin2
NCT07471165Possibly a fitNot yet recruiting

Testing a new drug combo before liver transplant for bile duct cancer

Locally Advanced Perihilar Cholangiocarcinoma

Part of Cancer, Digestive system clinical trials.

This trial tests whether giving a PD-L1 immunotherapy drug with chemotherapy and radiation before a liver transplant can help people with advanced bile duct cancer. The goal is to shrink the tumor and make a transplant possible.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
25 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old.
  • You have a type of bile duct cancer called perihilar cholangiocarcinoma that has spread locally but not to lymph nodes or other organs.
  • You have not had any prior cancer treatment like chemotherapy, radiation, or surgery for this cancer.
  • Your cancer must be measurable on scans, and you must be in fairly good health (able to do daily activities without help).
  • Your liver, kidney, and blood function tests need to be within certain safe ranges, and you must not have active infections or bleeding problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07328802Not yet recruiting· Phase 2
Testing a new drug combo for advanced bile duct cancer

This trial tests a combination of three medicines—an immunotherapy (sintilimab), an anti-angiogenic drug (bevacizumab), and two chemotherapy drugs (gemcitabine and cisplatin, called AG)—as a first treatment for bile duct cancer that cannot be removed by surgery. The goal is to see if this cocktail can shrink tumors or slow their growth better than standard therapy.

Hangzhou, Zhejiang
NCT06208462Recruiting· Phase 2
Combination therapy before surgery for high-risk bile duct cancer

This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.

Nanjing, Jiangsu
NCT07291947Recruiting· Phase 1/Phase 2
Radiation plus immunotherapy and chemotherapy for bile duct cancer

This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.

Chengdu, Sichuan
NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer

This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.

Oslo
NCT06910722Recruiting
Liver transplant for bile duct cancer after treatment

This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Before the transplant, you would receive radiation therapy (SIRT) and chemotherapy to shrink the tumor.

Clichy-sous-Bois
NCT06434493Not yet recruiting
Proton therapy and liver transplant for hilar bile duct cancer

This trial tests whether combining proton beam therapy (a precise type of radiation) with a liver transplant can help people with a certain bile duct cancer (hilar cholangiocarcinoma). It may be a new option for those who cannot have surgery to remove the cancer.

Hear when a new Locally Advanced Perihilar Cholangiocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.